greeksoup/ stock research
Stock research / United States / Funds / Revelation Capital Management, LLC

Revelation Capital Management, LLC

CIK 1801811 · latest 13F filed 14 August 2026 · Read the filing on EDGAR

Revelation Capital Management, LLC reported 2 US-listed holdings worth $109.5 million in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Omada Health Inc. (97.3%) and Artiva Biotherapeutics Inc. (2.7%). Against the quarter before, it opened 0 positions, added to 0, trimmed 1 and sold out of 0.

Reported holdings$109.5M+62.5% on Q1 2026
Positions2as many as Q1 2026
The largest ten100.0%of its reported holdings
Latest 13FQ2 2026filed 14 August 2026
Where the money is
HeldTrimmed
OMDA97.3%

The 2 largest of its 2 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.

Reported holdings, quarter by quarter
Q4 2025: $83.5 million in 2 positions$83.5MQ4 25Q1 2026: $67.4 million in 2 positions$67.4MQ1 26Q2 2026: $109.5 million in 2 positions$110MQ2 26

What the fund reported holding at each quarter's end; hover a bar for the number of positions

What its reported holdings returned

Held through each quarter, the holdings it reported returned +40.4% over the 2 quarters to 30 June 2026, against +9.5% for the S&P 500.

Its reported holdingsThe S&P 500
80100120140Q4 25Q1 26Q2 26Its holdings +40.4%S&P 500 +9.5%

Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.

What it did on the quarter

Held 1Trimmed 1
Held: 1Trimmed: 1

Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held

Trimmed 1

  1. Omada Health Inc. OMDA-350,000 shares · -7%

What it holds

CompanySharesValueOf its bookChange in shares
Omada Health Inc. OMDA4.9M$106.6 million97.35%-350.0K
Artiva Biotherapeutics Inc. ARTV299.3K$2.9 million2.65%no change
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.
Read moreChange is shares against its 13F for the quarter before.